# Gemseki

> Gemseki is a VC fund in Akasaka backing Health Care, Medical and Biotechnology. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Akasaka, Japan
- Total investments: 7
- Last investment: Feb 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/gemseki
- Website: https://www.gemseki.com/en

Gemseki is a portal platform company supporting the development of drug candidates. The company provides a Drug Candidate Marketplace platform, to support the best use of hidden and untapped drug candidates by bridging companies who would like to introduce and/or license out their drug candidates and companies who are eager to license in theknowledge of these candidates to develop valuable new drugs.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 71% |
| Medical | 4 | 57% |
| Biotechnology | 4 | 57% |
| Nursing and Residential Care | 2 | 29% |
| Analytics | 1 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 43% |
| Venture - Series Unknown | 2 | 29% |
| Seed | 1 | 14% |
| Series C | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 4 | 57% |
| United States | 2 | 29% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Avisi Technologies | Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $10.8M | Series A | Feb 25, 2026 |  |
| Cytonus Therapeutics | Cytonus Therapeutics is a biotech company that develops a therapeutic platform designed to treat immune-related disorders. The Cargocyte platform at Cytonus has diverse applications as it can be engineered to target specific tissues and can deliver strategic therapeutic payloads. | $11.7M | Series A | Nov 03, 2023 |  |
| Cellusion | Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system. | $20.3M | Series C | Jun 06, 2023 |  |
| Toregem BioPharma | Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia. Toregem BioPharma is headquartered in Kyoto, Japan. | $3.9M | Venture - Series Unknown | Mar 08, 2022 |  |
| Cellusion | Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system. | $9.5M | Venture - Series Unknown | Jan 06, 2022 |  |
| Curreio | Curreio develops contract business for structural analysis using cryo-electron microscopy. |  | Series A | Jun 23, 2021 |  |
| Cardio Intelligence | Cardio Intelligence develops an AI automated diagnostic system. | $1.3M | Seed | Mar 01, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund, 3 deals together
- [DBJ Capital](https://shizune.co/investors/profile/dbj-capital) — VC Fund, 2 deals together
- [UTEC - The University of Tokyo Edge Capital Partners](https://shizune.co/investors/profile/utec) — VC Fund, 2 deals together
- [Accanto Partners](https://shizune.co/investors/profile/accanto-partners) — VC Fund, 1 deal together
- [AIS CAPITAL](https://shizune.co/investors/profile/ais-capital) — VC Fund, 1 deal together
- [ANRI](https://shizune.co/investors/profile/anri) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gemseki invest in?

Gemseki invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gemseki last invest?

The most recent investment recorded for Gemseki closed in Feb 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co